U.S. markets closed

X4 Pharmaceuticals, Inc. (XFOR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7100+0.2200 (+14.77%)
At close: 04:00PM EDT
1.7101 +0.00 (+0.01%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.4900
Bid1.7200 x 800
Ask1.7300 x 3000
Day's Range1.4950 - 1.8591
52 Week Range0.8600 - 6.1800
Avg. Volume652,796
Market Cap117.385M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-3.4470
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XFOR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • X4 Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • Benzinga

    X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia

    X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in chronic neutropenia (CN) patients as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF). People with CN have a lower number of neutrophils, a type of white blood cell, for more than three months. 100% of study participants (n=25) responded to treatment with a s

  • GlobeNewswire

    X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

    100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across all CN disorders studied (idiopathic, cyclic, congenital); estimated diagnosed patient population ~ 50,000 in the U.S. Results suggest mavorixafor could be the first oral treatment for CN disorders and has the potential to reduce or replace injectable G-CSF, the current standard of care X4 to host investor w

  • GlobeNewswire

    X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

    Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&ABOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today announced that it will host an investor webinar to present and discuss new data from its Phase 1b trial evaluating its lead clinical candidate, mavorixafor, in patients with idiopathic, cy